Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen

被引:0
作者
Kobayashi, H
Omiya, R
Ruiz, M
Huarte, E
Sarobe, P
Lasarte, JJ
Herraiz, M
Sangro, B
Prieto, J
Borras-Cuesta, F
Celis, E
机构
[1] Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA
[2] Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 078, Japan
[3] Univ Navarra, Fac Med, Dept Med Interna, E-31080 Pamplona, Spain
[4] Univ Navarra, Clin Univ, Dept Med Interna, Pamplona 31008, Spain
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The product of the carcinoembryonic antigen (CEA) gene is an attractive candidate for T-cell-based immunotherapy because it is frequently expressed in epithelial solid carcinomas. Although many CEA peptide epitopes capable of stimulating CTLs have been identified, no MHC class II-restricted T helper epitope has yet been reported. Experimental Design: The amino acid sequence of CEA was examined for the presence of potential T helper epitopes, and candidate peptides were used to stimulate in vitro T-cell responses. Results: We describe here that using an algorithm to identify promiscuous helper T-cell epitopes, a peptide of CEA occupying residue positions 653 to 667 (CEA(653-667)), was effective in inducing in vitro T helper responses in the context of the HLA-DR4, HLA-DR7, and HLA-DR9 alleles. Most significantly, some of the peptide-reactive helper T lymphocytes were also capable of recognizing naturally processed antigen in the form of recombinant CEA protein or cell lysates from tumors that express CEA. Interestingly, the newly identified helper T-cell epitope was found to overlap with a previously described HLA-A24-restricted CTL epitope, CEA(652-660), which could facilitate the development of a therapeutic vaccine capable of eliciting both CTL and T helper responses in patients suffering from epithelial carcinomas. Conclusion: These results indicate that T helper lymphocytes are capable of recognizing CEA as a tumor antigen and that epitope CEA(653-667) could be used for immunotherapy against tumors expressing CEA.
引用
收藏
页码:3219 / 3225
页数:7
相关论文
共 49 条
[31]   Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen [J].
Marshall, JL ;
Hawkins, MJ ;
Tsang, KY ;
Richmond, E ;
Pedicano, JE ;
Zhu, MZ ;
Schlom, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :332-337
[32]   Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses [J].
Marshall, JL ;
Hoyer, RJ ;
Toomey, MA ;
Faraguna, K ;
Chang, P ;
Richmond, E ;
Pedicano, JE ;
Gehan, E ;
Peck, RA ;
Arlen, P ;
Tsang, KY ;
Schlom, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3964-3973
[33]   An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice [J].
Niethammer, AG ;
Primus, FJ ;
Xiang, R ;
Dolman, CS ;
Ruehlmann, JM ;
Ba, Y ;
Gillies, SD ;
Reisfeld, RA .
VACCINE, 2001, 20 (3-4) :421-429
[34]  
Nukaya I, 1999, INT J CANCER, V80, P92, DOI 10.1002/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.3.CO
[35]  
2-D
[36]   The role of CD4+ T cell responses in antitumor immunity [J].
Pardoll, DM ;
Topalian, SL .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (05) :588-594
[37]   T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions [J].
Schoenberger, SP ;
Toes, REM ;
van der Voort, EIH ;
Offringa, R ;
Melief, CJM .
NATURE, 1998, 393 (6684) :480-483
[38]   CEA-RELATED ANTIGENS - MOLECULAR-BIOLOGY AND CLINICAL-SIGNIFICANCE [J].
SHIVELY, JE ;
BEATTY, JD .
CRC CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1985, 2 (04) :355-399
[39]  
Southwood S, 1998, J IMMUNOL, V160, P3363
[40]  
TAKAMI N, 1988, J BIOL CHEM, V263, P12716